Logo image of CARM

CARISMA THERAPEUTICS INC (CARM) Stock Fundamental Analysis

NASDAQ:CARM - Nasdaq - US14216R1014 - Common Stock - Currency: USD

0.499  -0.01 (-1.13%)

After market: 0.4874 -0.01 (-2.32%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CARM. CARM was compared to 572 industry peers in the Biotechnology industry. CARM has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, CARM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CARM has reported negative net income.
In the past year CARM has reported a negative cash flow from operations.
In the past 5 years CARM always reported negative net income.
CARM had negative operating cash flow in 4 of the past 5 years.
CARM Yearly Net Income VS EBIT VS OCF VS FCFCARM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -151.70%, CARM is doing worse than 85.31% of the companies in the same industry.
Industry RankSector Rank
ROA -151.7%
ROE N/A
ROIC N/A
ROA(3y)-35.89%
ROA(5y)-44%
ROE(3y)-113.4%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CARM Yearly ROA, ROE, ROICCARM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CARM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CARM Yearly Profit, Operating, Gross MarginsCARM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K

More info and screens

2

2. Health

2.1 Basic Checks

CARM does not have a ROIC to compare to the WACC, probably because it is not profitable.
CARM has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CARM has more shares outstanding
The debt/assets ratio for CARM is higher compared to a year ago.
CARM Yearly Shares OutstandingCARM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
CARM Yearly Total Debt VS Total AssetsCARM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -13.43, we must say that CARM is in the distress zone and has some risk of bankruptcy.
CARM has a Altman-Z score of -13.43. This is amonst the worse of the industry: CARM underperforms 80.71% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.43
ROIC/WACCN/A
WACC11.96%
CARM Yearly LT Debt VS Equity VS FCFCARM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 3.23 indicates that CARM has no problem at all paying its short term obligations.
CARM has a Current ratio of 3.23. This is in the lower half of the industry: CARM underperforms 61.95% of its industry peers.
CARM has a Quick Ratio of 3.23. This indicates that CARM is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.23, CARM is not doing good in the industry: 60.18% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.23
Quick Ratio 3.23
CARM Yearly Current Assets VS Current LiabilitesCARM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

CARM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.40%, which is quite impressive.
The Revenue has grown by 90.67% in the past year. This is a very strong growth!
Measured over the past years, CARM shows a quite strong growth in Revenue. The Revenue has been growing by 9.90% on average per year.
EPS 1Y (TTM)58.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.51%
Revenue 1Y (TTM)90.67%
Revenue growth 3Y9.9%
Revenue growth 5YN/A
Sales Q2Q%-11.55%

3.2 Future

Based on estimates for the next years, CARM will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.56% on average per year.
Based on estimates for the next years, CARM will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y64.73%
EPS Next 2Y34.8%
EPS Next 3Y22.83%
EPS Next 5Y13.56%
Revenue Next Year58.08%
Revenue Next 2Y22.51%
Revenue Next 3Y-9.61%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CARM Yearly Revenue VS EstimatesCARM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0 0 0 0
CARM Yearly EPS VS EstimatesCARM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CARM. In the last year negative earnings were reported.
Also next year CARM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CARM Price Earnings VS Forward Price EarningsCARM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CARM Per share dataCARM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

CARM's earnings are expected to grow with 22.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.8%
EPS Next 3Y22.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CARM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARISMA THERAPEUTICS INC

NASDAQ:CARM (1/30/2025, 8:09:13 PM)

After market: 0.4874 -0.01 (-2.32%)

0.499

-0.01 (-1.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners31.8%
Inst Owner Change0.22%
Ins Owners2.48%
Ins Owner Change0%
Market Cap20.83M
Analysts78.33
Price Target5.78 (1058.32%)
Short Float %1.81%
Short Ratio1.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.93%
Min EPS beat(2)-16.89%
Max EPS beat(2)11.02%
EPS beat(4)2
Avg EPS beat(4)-0.6%
Min EPS beat(4)-16.89%
Max EPS beat(4)11.02%
EPS beat(8)5
Avg EPS beat(8)-2.8%
EPS beat(12)8
Avg EPS beat(12)36.08%
EPS beat(16)9
Avg EPS beat(16)34.77%
Revenue beat(2)1
Avg Revenue beat(2)45.2%
Min Revenue beat(2)-39.29%
Max Revenue beat(2)129.7%
Revenue beat(4)2
Avg Revenue beat(4)27.77%
Min Revenue beat(4)-39.29%
Max Revenue beat(4)129.7%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-42.18%
PT rev (3m)-25.44%
EPS NQ rev (1m)0%
EPS NQ rev (3m)47.48%
EPS NY rev (1m)0%
EPS NY rev (3m)0.5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)31.88%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.03
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.56
EYN/A
EPS(NY)-0.63
Fwd EYN/A
FCF(TTM)-1.64
FCFYN/A
OCF(TTM)-1.62
OCFYN/A
SpS0.49
BVpS-0.27
TBVpS-0.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -151.7%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.89%
ROA(5y)-44%
ROE(3y)-113.4%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.14%
Cap/Sales 3.38%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.23
Quick Ratio 3.23
Altman-Z -13.43
F-Score3
WACC11.96%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.51%
EPS Next Y64.73%
EPS Next 2Y34.8%
EPS Next 3Y22.83%
EPS Next 5Y13.56%
Revenue 1Y (TTM)90.67%
Revenue growth 3Y9.9%
Revenue growth 5YN/A
Sales Q2Q%-11.55%
Revenue Next Year58.08%
Revenue Next 2Y22.51%
Revenue Next 3Y-9.61%
Revenue Next 5Y-14.87%
EBIT growth 1Y10.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-811.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-804.08%
OCF growth 3YN/A
OCF growth 5YN/A